[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Why Wall Street Thinks This Dividend Stock Could Jump 30%

Biotechnology giant Amgen (AMGN) entered what it calls its “springboard year.” The company is facing a critical transition year with patent expirations and increasing biosimilar competition pressurizing its legacy products. But the company is now ready with a fast-growing portfolio of newer medicines that appears to be reshaping its future growth profile. And Wall Street expects this dividend-paying health care stock to climb roughly 30% from current levels.

Currently, Amgen stock is trading 13% below its 52-week high of $391.29. Let’s find out if this dividend stock is a buy on the dip now. 

Fundamentals

See More
  • Market Capitalization, $K 182,100,512
  • Shares Outstanding, K 539,685
  • Annual Sales, $ 36,751 M
  • Annual Income, $ 7,711 M
  • EBIT $ 10,568 M
  • EBITDA $ 16,935 M
  • 60-Month Beta 0.44
  • Price/Sales 4.87
  • Price/Cash Flow 9.81
  • Price/Book 19.47

Options Overview Details

View History
  • Implied Volatility 24.77% (+1.68%)
  • Historical Volatility 24.20%
  • IV Percentile 31%
  • IV Rank 25.10%
  • IV High 39.99% on 05/28/25
  • IV Low 19.66% on 08/15/25
  • Expected Move (DTE 7) 6.69 (1.97%)
  • Put/Call Vol Ratio 0.51
  • Today's Volume 4,624
  • Volume Avg (30-Day) 8,877
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 105,958
  • Open Int (30-Day) 102,887
  • Expected Range 332.39 to 345.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 36 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $5.60
  • Number of Estimates 12
  • High Estimate $6.23
  • Low Estimate $5.30
  • Prior Year $6.02
  • Growth Rate Est. (year over year) -6.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
320.52 +5.81%
on 05/05/26
350.69 -3.29%
on 04/23/26
-6.78 (-1.96%)
since 04/22/26
3-Month
320.52 +5.81%
on 05/05/26
391.29 -13.33%
on 03/02/26
-35.61 (-9.50%)
since 02/20/26
52-Week
267.83 +26.63%
on 06/23/25
391.29 -13.33%
on 03/02/26
+67.24 (+24.73%)
since 05/22/25

Most Recent Stories

More News
Why Wall Street Thinks This Dividend Stock Could Jump 30%

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

NVO : 44.86 (+1.06%)
LLY : 1,066.82 (+2.42%)
AMGN : 339.23 (+0.54%)
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment

Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.

NVDA : 216.83 (-1.22%)
GENB : 14.90 (+6.58%)
NVS : 152.47 (+0.47%)
AMGN : 339.23 (+0.54%)
AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

Thomas Dittrich Returning to Amgen as CFO

AMGN : 339.23 (+0.54%)
3 Large-Cap Stocks Worth Investigating

3 Large-Cap Stocks Worth Investigating

SNOW : 172.32 (+4.10%)
EME : 851.82 (+0.31%)
AMGN : 339.23 (+0.54%)
2 Cash-Producing Stocks on Our Watchlist and 1 We Turn Down

2 Cash-Producing Stocks on Our Watchlist and 1 We Turn Down

NFLX : 88.50 (-0.90%)
SCI : 77.20 (+0.61%)
AMGN : 339.23 (+0.54%)
FDA Commissioner Marty Makary Resigns Amid Leadership Turmoil and Biotech Industry Backlash

US Food and Drug Administration Commissioner Marty Makary is resigning after 13 months in the role, according to President Donald Trump, marking another leadership shakeup across federal health agencies....

KO : 81.41 (+0.30%)
MRNA : 47.12 (-0.30%)
AMGN : 339.23 (+0.54%)
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif. , May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m. PT on Wednesday, May 13, 2026. Peter...

AMGN : 339.23 (+0.54%)
5 Must-Read Analyst Questions From Amgen’s Q1 Earnings Call

5 Must-Read Analyst Questions From Amgen’s Q1 Earnings Call

AMGN : 339.23 (+0.54%)
2 Healthcare Stocks on Our Watchlist and 1 That Underwhelm

2 Healthcare Stocks on Our Watchlist and 1 That Underwhelm

TMO : 446.43 (-0.65%)
CAH : 200.29 (-0.16%)
AMGN : 339.23 (+0.54%)
Amgen Expands Puerto Rico Biologics Facility With Additional $300M Investment Amid Tariff Pressure

Amgen ($AMGN) is investing an additional $300 million to expand its biologics manufacturing facility in Puerto Rico, bringing its recent commitments to the site to nearly $1 billion as drugmakers increase...

NVS : 152.47 (+0.47%)
AMGN : 339.23 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 348.88
2nd Resistance Point 343.25
1st Resistance Point 340.34
Last Price 339.23
1st Support Level 331.80
2nd Support Level 326.17
3rd Support Level 323.26

See More

52-Week High 391.29
Fibonacci 61.8% 344.13
Last Price 339.23
Fibonacci 50% 329.56
Fibonacci 38.2% 314.99
52-Week Low 267.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.